Index

Abbott, F.M. 78, 237, 271, 272
Abraham, J. 77
Aiken case 195–6, 204
Andorra 84
Anti-counterfeiting Trade Agreement (ACTA) 24, 78
antitrust immunity, and intellectual property rights 78
Apostolopoulos, H. 78
appellation of origin 123
Argentina
burden of proof in process patent infringement cases 224–5
changes to patents regime 217
compulsory licenses 218–19
copyright laws 9
exclusive marketing rights 219–22
GMO soybean meal 46
import restrictions 222–3
injunctive relief 79
parallel imports 223
patentability
criteria in law 228
of micro-organisms 227–9
preliminary injunctions 225–7
product by process patent protection 223–4
protection of test data against unfair commercial use 230–31
transitional patents 229–30
USA patent dispute 216–31
Argentina – Patent Protection for Pharmaceuticals and Test Data Protection for Agricultural Chemicals 104, 227
Armenia 93
audiovisual works 8
Australia 20, 104–5
geographical indications 129, 130
Bahamas 84
‘A Balanced Interpretation of the “Three-step Test” in Copyright Law’ 281
Bartels, L. 18
Beckerman-Rodau, A. 75
Berne Convention for the Protection of Literary and Artistic Works 4, 14
minor exceptions doctrine 200
and TRIPS 197–8, 242, 244
Bhagwati, J. 287
Bhuiyan, S. 294
Biadgleng, E. 34, 60
bilateral agreements 9, 18, 106
bioequivalence 261
Blenko, W.J. 45
border measures 25
comparison of SECURE and TRIPS 29–30, 34
UPU Resolution 40 and TRIPS 36–7
implications of broad 42–6
under the TRIPS Agreement 25–8
UPU 35–6
WCO 28–9
Boyle, J. 280
Brazil 89
compulsory licenses 235
HIV/AIDS programme 233
industrial property law 232, 234
USA patent dispute 232–7
Brazil – Measures Affecting Patent Protection 232
Brussels Conference 199, 200, 201
Burk, D.L. 48
Cambodia 107, 108, 111
accession to WTO 110
administration of law 115
data protection 105, 106
stand-still principle 111
Canada
Patent Law 239
pharmaceutical inventions 240
Canada – Generics 271
application of
TRIPS Article 27.1 252–3
TRIPS Articles 28 and 30 in
stockpiling exception case 242–3
burden of proof, issues on 241–2
compatibility of Canadian Patent
Law with TRIPS 237
difference between regulatory
approval and stockpiling 265–70
discrimination as to the field of
technology 255–7
impact on clinical test data 263–5
implications for
domestic legislation 267–70
generic producers 258–63
legitimate interests 249–52
limited exception requirement 244,
245, 246, 247, 253, 262, 263
normal exploitation 247–9, 277,
279
regulatory review exception 238, 246,
249, 267, 270
rules of interpretation 241–2
stockpiling exception of Patent Act
238, 241, 242–3, 245, 246, 262,
274, 275, 279
and the Three-step test 270–71,
279
WTO panel analysis 213
Cape Verde 107, 108, 114
accession to WTO 110
commitments 112–13
stand-still principle 111
Carroll, M.W. 48, 49, 63, 68, 74
Carter, B.E. 293
Carvalho, N.P. de 221, 274, 275
Chapman, M. 55
Charlier, C. 139, 287
Chicago Convention on International
Civil Aviation (1944), Article 27
273, 275
Chile 213
China 92, 93, 94, 107
administration of law 114–15
criminal procedure to enforce IPR
97–8, 99
data protection 105–6
enforcement of IPRs 108
implementation of TRIPS 94–7
review of administrative decisions
and right of appeal 115–16
unfair use of data 105
China – Measures Affecting Imports of
Automobile Parts 118–19
China – Measures Affecting the
Protection and Enforcement of
Intellectual Property Rights 100,
104
Chinese Taipei 92, 93–4, 107
administration of law 115
alcohol and tobacco 108
Coco, R. 78
collective management organizations
(CMOs) 206, 207
commercial-scale counterfeiting and
piracy 99–100
compensatory liability regimes 260
compulsory licenses 56, 58, 59–60
Argentina 218–19
Brazil 235
opposition to 75–6
computer programs 14
Continental Paper Bag Co v. Eastern
Paper Bag Co. 52, 53–4
contracting parties 4
‘convoyed’ sales 62
copyright 50, 73–4, 276
and digital technology 212
exceptions and limitations 213
irreparable harm 66
purpose 192
refusal of injunctions 52–3
copyright law 9
Three-step test 281
Cornish, W.R. 123
Correa, C. 46, 107, 221, 236, 277, 286
Cottier, T. 286
‘counterfeit’, IMPACT definition 38–9
‘counterfeit medical products’ 37
definition 42
counterfeiting 5, 26, 42, 99
Creus, K. 213
criminal enforcement, IPRs 97–8
Cuba 283, 289
US – Section 211 Appropriations Act
of 1998 283–97
customs administrations
expansion of authority 40–41, 42
implications 44–6
damages
  assessing adequacy 61–6
  non-practising entities 63–5
  practicing entities 61–3
Dannay, R. 56, 64
DaSilva, R.J. 64
data, protection of undisclosed
  pharmaceutical and agrochemical
test data 101–7
‘data exclusivity’ 106, 231
databases 8
‘Declaration’ on ‘A Balanced
  Interpretation of the “Three-step
test” in Copyright Law’ 272
developed countries 83
developing countries 5, 83–4
  and geographical indications 129
  and SECURE 29–30
  standards 7
digital technology, and copyright
  212
Dinwoodie, G.B. 9, 11, 14
discretionary legislation 294–6
discrimination
de facto 256–7, 267
de jure 256, 267
meaning of term 255–6
term in TRIPS 269
Disney, H. 381
dispute settlement 4–5
  interpretation principles 19
  parallel imports 19–20
  under TRIPS 215–36
disputes
  USA–Argentina patent dispute
  216–31
  USA–Brazil patent dispute 232–7
‘diverted’ sales 62
Doctrine of Equivalents 45
Doha Declaration on the TRIPS
  Agreement and Public Health 10,
  233, 271, 280
Doha Round 97, 123, 128
  implementation issues 129
domestic law 7
  implications of Canada – Patent
  Protection of Pharmaceutical
  Products 267–70
  patent exceptions 272
Drahos, P. 6, 65
Dratler, J. 76
Dreyfuss, R. 9, 11, 14
eBay Inc. v. MercExchange LLC 53–4,
  56, 74
  right-remedy distinction 54
EC – GIs case 130–35
  findings under GATT 133–4
  implementation of panel findings
  135–7
  protection of pre-existing
  trademarks 134–5
Economides, N. 76
Ecuador 91
Ellis, D. 55, 66
emerging markets 83–4
‘entire market value’ rule 68
Epstein, R.A. 76
equitable jurisprudence, injunctive
  remedies 61–77
equity jurisprudence 48–9
Europe, geographical indications 126,
  127
European Communities, and
  geographical indications 8, 122–40
European Partnership Agreements
  (EPAs) 18
European Patent Office (EPO) 263, 270
exclusive marketing rights
  Argentina 219–22
  use of term 220–22
exclusive rights 19
exhaustion of rights 19
experimental use exemption 262
Fabricotti, A. 18
Faunce, T.A. 77
Fink, C. 263
foreign vessels exception 273, 275
France 126
Frankel, S. 9, 10, 11
Free Trade Agreements (FTAs) 16, 24,
  263, 265
  and intellectual property 9
  intellectual property chapters 20
  most favoured nation exemption
  17–18
G8 (Group of Eight) 25, 41
Gad, M.O. 60
Garnett, N. 213
Garrison, C. 237, 258, 261, 262, 265, 266, 271, 272, 273, 275
General Agreement on Tariffs and Trade (GATT) 23, 81, 118, 215–16, 294
applicability of jurisprudence to interpretation of TRIPS 3–23
disputes 3, 19
EC – GIs case 133–4
flexibilities 22
geographical indications 122
non-discrimination principles 13
tariffs as acceptable trade barriers 6
General Agreement on Trade in Services (GATS) 3, 5, 6
chapeau 22
non-discrimination principles 13
generic manufacturing 106, 268
generic producers 258–65
Geneva Convention for the Protection of Producers of Phonograms against Unauthorized Duplication of their Phonograms (1971) 113
Geographical Indications 15
geographical indications 8, 122
Café de Columbia 138
definition in TRIPS 124
and developing countries 129
disputes under TRIPS 128–30
economic interests and production systems 126–7
EU regulation (2006) 135–7
Europe 126, 127
as a form of intellectual property 124
and trademarks 123, 139–40
tradition and consumer perception 125–6
and TRIPS 123–7
and unfair competition 124–5
see also EC – GIs case
Gervais, D. 7, 17, 60
Ginsburg, J.C. 18, 196
Golec, J.H. 77
Gorman, R.A. 196
grandfathering (national exceptions) 199
Grimmett, J.J. 117
Hamilton, K. 63
Handbook on Accession to the WTO 84
Handler, M. 130, 138
Hasenzahl, C. 76, 268
Havana Club 16
Heald, P.J. 20
Herbert, W.N. 76
HIV/AIDS 233
Holzmann 45
Horn, H. 286
Howse, R.L. 12, 286, 287, 288
import restrictions, Argentina 222–3
in-transit seizures 44
India 268
counterfeit drugs 42–3
patent exceptions 258
Indian Pharmaceuticals Export Promotion Council (Pharmexcil) 42
infringement
continuing 73, 75
of intellectual property 51
infringing activity, judicial discretion to deny injunctions to stop 49–3
injunctions
intellectual property 67
judicial flexibility to deny 53–6
monitoring 66
‘ongoing royalty’ 56
patents 51–2
singnalling concerns 68
to inhibit continued infringement 67
injunctive relief 50, 51, 52, 66–7, 79
domestic policy flexibility under TRIPS 57–60
flexibility to deny 56
four-factor test 61
holdup-cost concerns 68
and judicial resources 67
national treatment 60
and public interest 73–4
regarding patent infringement 55
injunctive remedies, equitable jurisprudence 61–77
innovation 5, 7
intellectual property
enforcement law and standards, developed countries 25
implications of broad definition 42–3
increased standards 10–11
injunctions 67
intellectual property protection and barriers to trade 5–6
standards 7–8
intellectual property rights and antitrust immunity 78
commitments of countries acceding to WHO 87–114
criminal enforcement 97–8
enforcement 40
border measures 25
implications of expanded scope 43–4
expansion of scope of protection and enforcement 40
impact on public policy 280
and parallel imports 20
scope 8
International Civil Aviation (Chicago) exception 273
International Convention for the Protection of Performers, Producers of Phonograms and Broadcasting Organizations (Rome Convention) 4
international harmonization 293
and national treatment 295
international intellectual property agreements 4
International Medicinal Products Anti-counterfeit Taskforce (IMPACT) 24
international treaties, rules for interpretation 9
irreparable harm 65
assessing potential for 61–6
copyright 66
presumption 50, 51, 52, 54
Isaacs, D.H. 65
Jackson, J. 19
Jaffe, A.B. 278
Japan – Tariff on Import of Spruce-Pine-Fir (SPF) Dimension Lumber 13
Japan – Taxes on Alcoholic Beverages 3, 12, 15
Jarosz, D.E.J. 55
Jordan 92
Joseph, L. 43
Josling, T. 126
judicial flexibility, to deny injunctions 53–6
Keener Hughen, W. 77
Keller, E. 63
Laing, S. 128
least-developed countries (LDCs) 83, 84
IP rights issues in accession to WTO 109–14
legislation, mandatory and discretionary 294–6
legitimate interests, meaning of term 249–52, 278
Lemley, M.A. 48, 51, 68
Lerner, J. 278
Lewis, T. 260
lex specialis 15, 23
Li, X. 25, 30
liability rules, and property rules 65
like products and services, notion 12, 13
‘limited’, definition of 271
limited exception requirement 149, 244, 245, 246, 247, 253, 262, 263, 275, 276
limited exceptions, meaning of term 244–6, 273, 274
‘linkage requirements’ 107
Lisbon Agreement 124
Macedonia 93
Madrid Agreement 124
‘mailbox’ system, patents 220, 222
mandatory and discretionary, legislation 294–6
Marrakesh Agreement 3, 81
Maskus, K.E. 260
Mattson, J.E. 216
Mavroidis, P.C. 286
Max Planck Institute for Intellectual Property 214, 281
Meir, P. 261
Merck v. Integra lifesciences 259, 261–2
micro-organisms, patentability 227–9
minor exceptions doctrine 198–200
most-favoured nation 11–14, 84, 94, 255, 285, 293
in GATT and GATS 12
TRIPS’ lack of exception 17–19
WTO panels and TRIPS 15–16
Mueller, J.M. 268
Munoz, V. 34

national drug authorities (DRA) 261, 264
national exceptions, grandfathering 199
national treatment 11–14, 84, 131–3, 255, 285
in GATT and GATS 12
injunctive relief 60
and international harmonization 295
reciprocity 288
in TRIPS 287–8
and unilateralism 293–4
in US – Section 211 Appropriations Act of 1998 286–96
WTO panels and TRIPS 15–16
Negro, S.C. 217
Nepal 107, 108
accession to WTO 110, 113
administration of law 115
stand-still principle 111
Neven, D.J. 286
new world countries 122, 130
New Zealand, copyright laws 9
Ngo, M.A. 139, 287
Nielsen, C.M. 75
non-discrimination principles 13
non-practising entities, damages 63–5, 68
‘normal’, interpretation of term in US – Copyright 279
‘normal business losses’ 66
‘normal exploitation’ 205–6, 277–8
meaning of term 247–9, 277
North American Free Trade Agreement (NAFTA) 268

OECD 269
Oman 92
‘ongoing royalty’ injunctions 56, 59, 76

Panama 92
parallel imports 7, 19–20, 23, 223
and intellectual property rights 20
Paris Convention for the Protection of Industrial Property 4, 102, 124, 283, 287
Article 2 286
Article 5 235–6
Article 5ter 273
Article 10bis 25, 103, 231
‘unfair commercial use’ 231
passing off doctrine 123
patent exceptions 258, 275
under domestic law 272
patent infringement
determination 45
injunctive relief 55
patent law, traditional knowledge in 8
patent rights
definition 221
in TRIPS 253
patent rules, and technological developments 270
patentability 14
micro-organisms 227–9
requirements 268–9
patents 54, 77
assessment of damages 61–6
injunctions 51–2
‘mailbox’ system 220, 222
pharmaceuticals 260
product by process patent protection 223–4
burden of proof in infringement cases 224–5
subject matter discrimination 13
USA–Argentina patent dispute 216–31
USA–Brazil patent dispute 232–7
Patry, W.F. 53
Pharmaceutical Research and Manufacturers of America (PhRMA) 234
pharmaceuticals
Europe, IP protection and registration 107
generic producers 106
local production 269–70
patents 260
Index

protection of undisclosed pharmaceutical and agrochemical test data 101–7
stockpiling 240
USA–Argentina patent dispute 215–31
pharmacy exception 275–6
piracy 26, 99
practicing entities, damages 61–3
Prakash-Canjels, G. 63
preliminary injunctions, Argentina 225–7
process patent protection 223–4
property rules, and liability rules 65
Provisional Standards Employed by Customs for Uniform Rights Enforcement (SECURE) 25, 29
compared to TRIPS 29–34
enforcement 30
infringing goods 34
and right-holders 30–31
scope of protection 30
standards 29, 30
as a threat to developing countries 29
TRIPS-plus-plus elements 30
proximate causation 62
public interest, and injunctive relief 73–4
Pugatch, M.P. 281
Rader, J. 56
Rangenekar, D. 126
‘reasonable royalty’ 64
‘reference right’ 106
regulatory review exception 258–63
compared to stockpiling exception 265–70
Reichenmiller, P. 263
Reichman, J.H. 17, 76, 79, 260, 264, 268
Resource Book on TRIPS 123, 124
retail differentiation 48
Ricketson, S. 18, 212, 213
rights centred approaches 280
Robertson, M.D. 76
Robinson, W.C. 51, 57
Roessler, F. 287
Roffe, P. 263
Rome Convention for the Protection of Performers, Producers of Phonograms and Broadcasting Organizations 4, 212
Russia 84
law ‘On the Procedure for Consideration of Appeals by Citizens of the Russian Federation’ 80
Rwanda, patent exceptions 258
Ryan, D.F. 52
Samardzija, M.R. 75
Santilli, M. 64
Sarnoff, J.D. 77
Saudi Arabia
accession to WTO 88–9, 90, 92
administration of law 115
‘Scenarios for the Future’ (EPO) 270
Schneider, M. 26
Schoenhar, P.M. 53
Scotchmer, S. 288
Scott Oliver, L. 55
SECURE see Provisional Standards Employed by Customs for Uniform Rights Enforcement (SECURE)
Sell, S. 5
Senftleben, M. 200, 272, 276, 277, 278, 279
Seychelles 84
Shapiro, C. 51, 68
Shashikant, S. 39
small/vulnerable island economies 83
Spain 126
Spenneman, C. 128, 264
Sterk, S.E. 65
Stiefel, A. 65
Stockholm Conference 199, 201
stockpiling exception 262
compared to regulatory review exception 265–70
Story, J. 48, 49
Sullivan, J. 213
Swiss Patents Act 262
Tanzania, patent exceptions 258
technological developments, and patent rules 270
technology transfer 5, 278
‘terroir’ 126
Carlos M. Correa - 9781849806602
Downloaded from Elgar Online at 03/21/2019 10:20:40PM
via free access
test data  
impact of Canada – Patent Protection of Pharmaceuticals 263–5  
protection against unfair commercial use 230–31  
Thomas, J.R. 263  
Thrumm, N. 280  
Timmermans, K. 264  
Tonga 107, 111  
accession to WTO 110  
data protection 105, 106  
stand-still principle 111  
trade retaliation 5  
Trade-related Aspects of Intellectual Property Rights (TRIPS) Agreement  
Active Pharmaceutical Ingredients (SPI) 43  
applicability of GATT jurisdiction to interpretation 3–23  
Article 1 124  
Article 2 284  
Article 3 7, 286, 287  
Article 4 7  
Article 6 7  
Article 7 278, 279  
Article 13 213, 276  
  scope of the three-step test 200–203, 213  
Article 13 special cases 202–3  
Article 16 134  
Article 17 276  
Article 22 124  
Article 23 125  
Article 24 125, 134  
Article 27 21, 228, 232, 234, 235, 239, 240, 267  
  anti-discrimination provision 234, 269, 271  
  interpretation 14–15  
  patentability criteria 228–9  
Article 27.1, applicability to Article 30 exceptions 253–5  
Article 28 222, 232, 234, 235, 240–41, 267  
  application in regulatory review exception case 246–7  
  application in stockpiling exception case 242–3  
Article 30 14, 242, 266–7  
  application in regulatory review exception case 246–7  
  application in stockpiling exception case 242–3  
  legitimate interests 249–52  
  limited exceptions 244–6  
  normal exploitation 247–9  
  object and purpose 243–4  
  three-step test 270–71, 272–3, 276  
Article 31(k) 218–19  
Article 34 224–5  
Article 39 101–7, 230, 264  
Article 44 58, 59, 60, 64  
Article 45 58, 64  
Article 46 36  
Article 50 225–6  
Article 51 26, 108  
Article 52 26–7  
Article 54, Notice of Suspension 27  
Article 55, Notice of Suspension 27  
Article 58 27  
  authority of customs administrations 27  
Article 59, remedies for right-holders 27  
Article 60, exceptional circumstances 27–8  
Article 61 97–8, 99–100, 108  
Article 62 111  
Article 65 91, 110, 220, 230  
Article 70 220–21, 222, 229–30  
  balancing principles 10  
  and Berne Convention 197–8  
  border measures 25–8  
  members’ obligations 26  
  commitments for full implementation 90  
  compared to SECURE 29–34  
  compared to UPU Resolution 40 36–7  
copyright, three-step test 191  
dispute settlement 215–36  
  domestic policy flexibility for injunctive relief 57–60  
  enforcement authorities 60  
  exceptions to exclusive rights 21–3  
  flexibilities 5, 78  
  full implementation 93  
  geographical indications 122, 123–7
built-in agenda 128

disputes 128–30

lack of most favoured nation exception 17–19

minimum standards 6, 7–11

interpretation 11–14

national treatment 131–3, 287

non-discrimination principles 10, 13

object and purpose 10

patent protection for pharmaceutical products 91–2

relationship with GATT 5

structure compared with GATT and GATS 7–19

three-step test 21

see also World Trade Organisation (WHO)

trademarks 50, 127, 276, 283, 285

and geographical indications 123, 139–40

goodwill and reputation 65–6

protection of pre-existing trademarks 134–5

US – Section 211 Appropriations Act of 1998 283–97

traditional knowledge 126

in patent law 8

transition economies 83, 91

transitional patents, Argentina 229–30

Treaty in Intellectual Property in Respect of Integrated Circuits 4

Trebilcock, M.J. 12, 287, 288

TRIPS-plus-plus standards comparison on IP enforcement at WCO, UPU, and WHO 41

on IP enforcement 24

Ukraine 93, 106, 107

administration of law 115

Law on Medicines 105

UNCTAD 258

UNCTAD–ICTSD 259, 269

unfair competition 103, 123

and geographical indications 124–5

unilateralism, and national treatment 293–4

United International Bureaux for the Protection of Intellectual Property (BIRPI) 199

United States – Measure Affecting

Imports of Woven wool shirts and Blouses from India 242

United States – US Patents Code 232

Universal Postal Union (UPU) 24, 35

Resolution 40, 35–7

compared to TRIPS 36–7

Uruguay Round 80, 128

Trade-offs 125

US Measures Affecting the Importation, Internal sale and Use of Tobacco 294

US – Anti-dumping Act of 1916 294

US – Copyright 278–9

interpretation of term ‘normal’ 279

US – Section 211 Appropriations Act of 1998 283–97

case of original owners 290–92

international harmonization 293

mandatory and discretionary legislation, distinction 294–6

most favoured nation obligation 293

most-favoured-nation obligation 293

national treatment principle in AB report 286–96

successors-in-interest to original owners 289–90

unilateralism 293–4

US – Section 337 290

USA

Argentina patent dispute 216–31

Brazil patent dispute 232–7

and China 99, 100

Code of Federal Regulations (CFR) 283

compulsory licensing 58

Copyright Act

business exception 194, 203–4, 205, 206–7, 210–11

homestyle exception 194–5, 196, 204–5, 207–9

Section 106 193

Section 110(5) 142–90

and TRIPS 211

as a violation of TRIPS 192

copyright laws 9

copyright Royalty Board 76

Court of Appeals for the Federal circuit 49, 50, 51, 53, 54, 73, 76

Cuban Assets Control Regulations (CACR) 283, 289
Fairness in Music Licensing Act (1998) 196
geographical indications 129, 130
Hatch-Waxman Act 77, 238
injunctive relief case law 57–8
Office of Foreign Assets Control (OFAC) 283, 289, 290, 292, 293, 295
Omnibus Appropriation Act (1998), Section 211 283–4
Patent Act (1819) 57
Special 301 Priority Watch List 234
Supreme Court 55, 54, 55
Trading with the Enemy Act (1917) 283
trial courts, discretionary authority 57
USPTO 263
validity, legitimate challenges to 69
Vanuatu 84
Vernon, J.A. 77
Vienna convention, Articles 31 and 32 241–2
Vienna Convention on the Law of Treaties 9, 247
Viet Nam 93, 97, 107
criminal enforcement of IPR 98–9
software and government agencies 109
Vivas-Engui, D. 128
Vrins, O. 26
Wechkin, J.M. 77
Wegner, H.C. 59
Weissman, R. 106
Westkamp, G. 8
Wetzler, J. 233
Whitaker, L. 75
wines and spirits 124, 125
World Customs Organization (WCO) 24, 28–9
SECURE 29–30, 34
World Health Assembly (WHA) 42
‘Global strategy and plan of action on public health, innovation and intellectual property’ 280
World Health Organization (WHO) 23, 24, 37
IMPACT 37–9
comparison of counterfeit medical product and TRIPS 39
definition of ‘counterfeit’ 38
World Intellectual Property Organization (WIPO) 7, 24
Copyright Treaty 185, 212
Development Agenda 213, 281
exceptions and limitations to copyright 213
full implementation of TRIPS 93–7
geographical names 124
Performers and Phonograms Treaty 212
and WTO 25
World Trade Organisation (WTO) 3, 4, 24, 60
accession to 85–6
report on US – Section 211 Appropriations Act of 1998 286–96
background 60–61
commitment beyond the full implementation of TRIPS 101
commitments of acceding countries on IPRs 87–114
dispute on EC – Protection of Trademarks and Geographical Indications for Foodstuffs (EC – GI) 122
Dispute Settlement Body 19, 97, 191, 215, 237
findings of panel 210–11
panel report on copyright dispute 191
business exception 191
homestyle exception 191
implementation 211–12
Dispute Settlement Body (DSB), US – Section 211 Appropriations Act of 1998 283
Dispute Settlement Understanding (DSU) 5, 9, 19, 23, 117, 216
enforcement of commitments under accession process 117–19
full implementation of TRIPS, as understood by the Working Party on Enforcement 97–100
General Council 215
implementation of TRIPS 90–93
Index

LDCs, accession 109–14
legislative practices and administration of laws 114–15
membership 81–2
Ministerial conference 215
new accession procedures 82
and recent developments 83–7
original members 81–2
result based IP enforcement obligation 107–9
review of administrative decisions and right of appeal, China 115–16
stand-still principle 111
transition period for TRIPS implementation 90–93
USA–Argentina patent dispute 216–31

burden of proof in process infringement cases 224–5
compulsory licenses 218–19
exclusive marketing rights 219–22
import restrictions 222–3
mutually agreed solution 217–18
patentability of micro-organisms 227–9
preliminary injunctions 225–7
product by process patent protection 223–4
protection of test data against unfair commercial use 230–31
transitional patents 229–30
USA–Brazil patent dispute 232–7
mutually agreed solution 232–3
and WIPO 25
Working Party Report documents 88